Ignite Creation Date:
2025-12-24 @ 4:40 PM
Ignite Modification Date:
2025-12-28 @ 11:51 AM
Study NCT ID:
NCT05978466
Status:
RECRUITING
Last Update Posted:
2024-01-18
First Post:
2019-04-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
MANAGE-AF Registry -MANAGEment of Atrial Fibrillation Outcomes Registry (MANAGE-AF)
Sponsor:
CorVita Science Foundation
Organization:
Study Overview
Official Title:
MANAGEment of Atrial Fibrillation Outcomes Registry (MANAGE-AF)
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MANAGE-AF
Brief Summary:
The purpose of this research is to learn more about the normal care of patients with a new or pre-existing diagnosis of atrial fibrillation (AF). These abnormal and irregular heartbeats place patients at increased risk of developing clots in their bloodstream that could potentially lead to stroke. Normal care is designed to help prevent this from happening and to lessen or eliminate the symptoms patients may have. There are many different types of AF as well as numerous ways in which a variety of patients are treated. The investigators are interested in gathering more information to better keep track of patient treatment patterns (trends) that may differ from physician to physician, hospital to hospital, medication to medication, patient to patient and if necessary, procedure to procedure.
Detailed Description:
The objective of this research is to establish a contemporary and simple to construct AF management registry that expands progressively over the continuum of care for each individual patient. The registry will be used to determine the course and progression of AF management in preventing thrombo-embolic events using rhythm and rate control interventions.
Primary endpoints:
1. Atrial fibrillation natural history
2. Thrombo-embolic event
3. Death
Secondary endpoints:
1. Bleeding
2. Pro-arrhythmia
3. Patient adherence
4. Treatment complication
Primary endpoints:
1. Atrial fibrillation natural history
2. Thrombo-embolic event
3. Death
Secondary endpoints:
1. Bleeding
2. Pro-arrhythmia
3. Patient adherence
4. Treatment complication
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: